Perrigo Company plc
PRGO Healthcare Drug Manufacturers Specialty & Generic
Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024. In the quarter to June 2026, revenue fell 3.17%, EPS grew 1,000.0%, free cash flow grew 18.4% and total debt fell 9.78%, each against the same quarter a year earlier. Dividend growth for ten consecutive years; insiders bought in the last twelve months.
Follow PRGO
Perrigo Company plc (PRGO) EV/Sales
As of 16 October 2026, Perrigo Company plc (PRGO) trades at a EV/Sales of 1.3×. Over the past ten years it has ranged from 1.0× (July 2026) to 10.4× (January 2016); the current reading is higher than 8% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.2× | (21.44%) |
| FY2024 | 1.5× | (10.15%) |
| FY2023 | 1.7× | (9.39%) |
| FY2022 | 1.9× | 11.82% |
| FY2021 | 1.7× | (24.96%) |
| FY2020 | 2.2× | (14.97%) |
| FY2019 | 2.6× | 52.87% |
| FY2018 | 1.7× | (45.57%) |
| FY2017 | 3.1× | (6.28%) |
| FY2016 | 3.3× | (67.18%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.0× | (8.17%) |
| Mar 2026 | 1.1× | (3.70%) |
| Dec 2025 | 1.2× | (19.48%) |
| Sep 2025 | 1.5× | (7.67%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −0.1× |
| PRGO Perrigo Company plc | 1.3× |
| ANIP ANI Pharmaceuticals, Inc. compare | 1.8× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 2.6× |
| SUPN Supernus Pharmaceuticals, Inc. compare | 2.8× |
| PBH Prestige Consumer Healthcare Inc. compare | 3.9× |
| XERS Xeris Biopharma Holdings, Inc. compare | 5.7× |
| LQDA Liquidia Corporation compare | 6.5× |
| ALVO Alvotech compare | 9.0× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)